Scientists engineer mosquito immune system to fight malaria

December 22, 2011, Public Library of Science

Researchers at the Johns Hopkins Malaria Research Institute have demonstrated that the Anopheles mosquito's innate immune system could be genetically engineered to block the transmission of malaria-causing parasites to humans. In addition, they showed that the genetic modification had limited impact on the mosquito's fitness under laboratory conditions. The researchers' findings are published December 22nd in the Open Access journal PLoS Pathogens.

In this study, Dimopoulos and his team genetically engineered Anopheles mosquitoes to produce higher than normal levels of an Rel2 when they feed on blood. Rel2 acts against the in the mosquito by launching an immune attack involving a variety of anti-parasitic molecules. Through this approach, instead of introducing a new gene into the mosquito DNA, the researchers used one of the insect's own genes to strengthen its parasite-fighting capabilities.

According to the researchers, this type of genetically modified mosquito could be further developed and used to convert malaria-transmitting to Plasmodium-resistant mosquito populations. One possible obstacle for this approach is the fitness of the genetically modified malaria resistant mosquitoes, since they would have to compete with the natural malaria-transmitting mosquitoes. The researchers showed with their study that the Rel2 genetically modified mosquito strain lived as long, and laid as many eggs, as the non-modified wild type mosquitoes, thereby suggesting that their fitness had not become significantly impaired.

"Malaria is one of world's most serious public health problems. Mosquitoes and the malaria parasite are becoming more resistant to insecticides and drugs, and new control methods are urgently needed. We've taken a giant step towards the development of new mosquito strains that could be released to limit , but further studies are needed to render this approach safe and fail-proof," said Dimopoulos.

Explore further: Wolbachia bacteria reduce parasite levels and kill the mosquito that spreads malaria

Related Stories

Wolbachia bacteria reduce parasite levels and kill the mosquito that spreads malaria

May 19, 2011
Wolbachia are bacteria that infect many insects, including mosquitoes. However, Wolbachia do not naturally infect Anopheles mosquitoes, which are the type that spreads malaria to humans. Researchers at the Johns Hopkins Bloomberg ...

Certain bacteria render mosquitoes resistant to deadly malaria parasite

May 12, 2011
cientists have identified a class of naturally occurring bacteria that can strongly inhibit malaria-causing parasites in Anopheles mosquitoes, a finding that could have implications for efforts to control malaria. The study, ...

Recommended for you

Improving vaccines for the elderly by blocking inflammation

January 22, 2018
By identifying why skin immunity declines in old age, a UCL-led research team has found that an anti-inflammatory pill could help make vaccines more effective for elderly people.

Novel genomic tools provide new insight into human immune system

January 19, 2018
When the body is under attack from pathogens, the immune system marshals a diverse collection of immune cells to work together in a tightly orchestrated process and defend the host against the intruders. For many decades, ...

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.